$JFBR
Jeffs' Brands Ltd Stock $jfbr

$jfbr Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024028253 Filed on April 01, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$10.01M	$10.01M	$5.859M
YoY Change	70.81%	70.81%	-9.99%
Cost Of Revenue	$9.032M	$9.032M	$5.060M
YoY Change	78.5%	78.5%	10.96%
Gross Profit	$976.0K	$976.0K	$799.0K
YoY Change	22.15%	22.15%	-59.0%
Gross Profit Margin	9.75%	9.75%	13.64%
Selling, General & Admin	$5.095M	$5.095M	$5.311M
YoY Change	-4.07%	-4.07%	90.09%
% of Gross Profit	522.03%	522.03%	664.71%
Research & Development		$169.0K
YoY Change
% of Gross Profit		17.32%
Depreciation & Amortization	$735.0K	$738.0K	$286.0K
YoY Change	156.99%	29.47%	2.14%
% of Gross Profit	75.31%	75.61%	35.79%
Operating Expenses	$4.816M	$5.095M	$5.311M
YoY Change	-9.32%	-4.07%	84.35%
Operating Profit	-$3.840M	-$5.089M	-$4.512M
YoY Change	-14.89%	12.79%	384.12%
Interest Expense	-$726.0K	-$716.0K	$2.305M
YoY Change	-131.5%	-130.08%	-466.45%
% of Operating Profit
Other Income/Expense, Net		$523.0K
YoY Change		-797.33%
Pretax Income	-$4.566M	-$4.566M	-$2.207M
YoY Change	106.89%	76000.0%	41.38%
Income Tax	$32.00K	$32.00K	-$6.000K
% Of Pretax Income
Net Earnings	-$4.598M	-$4.598M	-$2.201M
YoY Change	108.91%	108.91%	42.92%
Net Earnings / Revenue	-45.94%	-45.94%	-37.57%
Basic Earnings Per Share		-$3.88
Diluted Earnings Per Share	-$3.88	-$3.88	-$0.47
COMMON SHARES
Basic Shares Outstanding	1.216M shares	1.184M shares	8.074M shares
Diluted Shares Outstanding		1.184M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$535.0K	$535.0K	$8.137M
YoY Change	-93.43%	-93.43%	1970.48%
Cash & Equivalents	$535.0K	$535.0K	$8.137M
Short-Term Investments
Other Short-Term Assets	$17.00K	$576.0K
YoY Change
Inventory	$2.386M	$2.386M	$1.791M
Prepaid Expenses
Receivables	$629.0K	$629.0K	$327.0K
Other Receivables	$597.0K	$38.00K	$779.0K
Total Short-Term Assets	$4.164M	$4.164M	$11.03M
YoY Change	-62.26%	-62.26%	445.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$59.00K	$186.0K	$41.00K
YoY Change	43.9%	3.91%	1266.67%
Goodwill
YoY Change
Intangibles	$5.714M		$4.452M
YoY Change	28.35%		-11.33%
Long-Term Investments	$1.940M	$2.007M
YoY Change
Other Assets	$168.0K	$168.0K	$110.0K
YoY Change	52.73%	52.73%	-69.95%
Total Long-Term Assets	$8.075M	$8.075M	$4.741M
YoY Change	70.32%	70.32%	-12.04%
TOTAL ASSETS
Total Short-Term Assets	$4.164M	$4.164M	$11.03M
Total Long-Term Assets	$8.075M	$8.075M	$4.741M
Total Assets	$12.24M	$12.24M	$15.78M
YoY Change	-22.42%	-22.42%	112.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$709.0K	$709.0K	$131.0K
YoY Change	441.22%	441.22%	-21.56%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$86.00K
YoY Change	-100.0%	-100.0%	-90.72%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.308M	$2.308M	$640.0K
YoY Change	260.63%	260.63%	-71.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.420M	$1.420M	$2.314M
YoY Change	-38.63%	-38.63%
Total Long-Term Liabilities	$1.420M	$1.420M	$2.314M
YoY Change	-38.63%	-38.63%	-36.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.308M	$2.308M	$640.0K
Total Long-Term Liabilities	$1.420M	$1.420M	$2.314M
Total Liabilities	$3.728M	$3.728M	$2.954M
YoY Change	26.2%	26.2%	-52.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.276M		-$3.678M
YoY Change	125.01%		149.02%
Common Stock	$16.79M		-$3.319M
YoY Change	-605.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.511M	$8.511M	$12.82M
YoY Change
Total Liabilities & Shareholders Equity	$12.24M	$12.24M	$15.78M
YoY Change	-22.42%	-22.42%	112.83%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$4.598M	-$4.598M	-$2.201M
YoY Change	108.91%	108.91%	42.92%
Depreciation, Depletion And Amortization	$735.0K	$738.0K	$286.0K
YoY Change	156.99%	29.47%	2.14%
Cash From Operating Activities	-$1.499M	-$2.668M	-$3.786M
YoY Change	-60.41%	-44.88%	587.11%
INVESTING ACTIVITIES
Capital Expenditures	$16.00K	$25.00K	$38.00K
YoY Change	-57.89%	-39.02%	-2000.0%
Acquisitions
YoY Change
Other Investing Activities	-$115.0K	-$3.108M
YoY Change
Cash From Investing Activities	-$131.0K	-$4.814M	-$38.00K
YoY Change	244.74%	11641.46%	1800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-$86.00K	11.89M
YoY Change	-100.0%	-100.68%	1394.22%
NET CHANGE
Cash From Operating Activities	-1.499M	-$2.668M	-3.786M
Cash From Investing Activities	-131.0K	-$4.814M	-38.00K
Cash From Financing Activities	0.000	-$86.00K	11.89M
Net Change In Cash	-1.630M	-$7.568M	8.070M
YoY Change	-120.2%	-197.73%	3220.99%
FREE CASH FLOW
Cash From Operating Activities	-$1.499M	-$2.668M	-$3.786M
Capital Expenditures	$16.00K	$25.00K	$38.00K
Free Cash Flow	-$1.515M	-$2.693M	-$3.824M
YoY Change	-60.38%	-44.83%	596.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1184484	shares
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41482
CY2023	dei	Entity Registrant Name EntityRegistrantName	Jeffs’ Brands Ltd
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Mezada Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Bnei Brak
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Israel
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	5126112
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1215512	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15775000	usd
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	1197
CY2023	dei	Auditor Name AuditorName	Brightman Almagor Zohar & Co.
CY2023	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8137000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	17000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	629000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	327000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	597000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	779000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2386000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1791000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4164000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11034000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1940000	usd
CY2023Q4	us-gaap	Other Investments OtherInvestments	67000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5714000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4452000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	168000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	110000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	127000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	138000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	8075000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	4741000	usd
CY2023Q4	us-gaap	Assets Assets	12239000	usd
CY2022Q4	us-gaap	Assets Assets	15775000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	709000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	131000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1533000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	391000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	66000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	32000	usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	86000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2308000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	640000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1375000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2216000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	98000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1420000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2314000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3728000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2954000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	43567567	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	43567567	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1215512	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1215512	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1153461	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1153461	shares
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	16787000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	16499000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8276000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3678000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8511000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12821000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12239000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10008000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5859000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6509000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	9032000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5060000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	4560000	usd
CY2023	us-gaap	Gross Profit GrossProfit	976000	usd
CY2022	us-gaap	Gross Profit GrossProfit	799000	usd
CY2021	us-gaap	Gross Profit GrossProfit	1949000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	833000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1198000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1314000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4262000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4113000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1480000	usd
CY2023	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	1249000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	87000	usd
CY2023	jfbr	Other Operating Incomeloss OtherOperatingIncomeloss	-279000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5089000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4512000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-932000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	523000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2305000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-629000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4566000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2207000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1561000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4598000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2201000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1540000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.88
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.73
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1184484	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	663411	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	413192	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	350000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1540000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	75000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1250000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	60000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1058000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1253000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2201000	usd
CY2022	jfbr	Adjustmentsto Additional Paid In Capital Debt Extinguishment AdjustmentstoAdditionalPaidInCapitalDebtExtinguishment	769000	usd
CY2022	jfbr	Stock Issued During Period Issuance Of Ordinary Shares Upon Initial Public Offering Net Of Issuance Costs StockIssuedDuringPeriodIssuanceOfOrdinarySharesUponInitialPublicOfferingNetOfIssuanceCosts	6194000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	26000	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	3461000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	3319000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12821000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4598000	usd
CY2023	jfbr	Stock Issued During Period Issuance Of Ordinary Shares StockIssuedDuringPeriodIssuanceOfOrdinaryShares	288000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8511000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4598000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2201000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1540000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	60000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-34000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	738000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	570000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	524000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	87000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	298000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	546000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	14000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	221000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1249000	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	841000	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	2822000	usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	-75000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	25000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-58000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-115000	usd
CY2022	jfbr	Issuance Costs On Derivative Liabilities IssuanceCostsOnDerivativeLiabilities	1416000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	302000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-39000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	282000	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	40000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-182000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	743000	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	290000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	596000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	564000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	449000	usd
CY2022	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	-213000	usd
CY2021	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	241000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1304000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-579000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	254000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-67000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-14000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-67000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-15000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2668000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4840000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-863000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
CY2023	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	17000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	3091000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1681000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4728000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4814000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4730000	usd
CY2022	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	752000	usd
CY2021	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	981000	usd
CY2023	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	86000	usd
CY2022	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	1518000	usd
CY2021	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	134000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13391000	usd
CY2021	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	4800000	usd
CY2021	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	100000	usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-1102000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1250000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-86000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12625000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5695000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7568000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	7744000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	102000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-34000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8137000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	393000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	535000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8137000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	393000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	28000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	73000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	116000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	477000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	4000	usd
CY2021	jfbr	Deferred Offering Costs Included In Other Payables DeferredOfferingCostsIncludedInOtherPayables	86000	usd
CY2021	jfbr	Sharebased Compensation Included In Deferred Offering Costs SharebasedCompensationIncludedInDeferredOfferingCosts	75000	usd
CY2022	jfbr	Issuance Of Ordinary Shares Upon Conversion Of Shareholders Loans IssuanceOfOrdinarySharesUponConversionOfShareholdersLoans	2839000	usd
CY2023	jfbr	Issuance Of Ordinary Shares IssuanceOfOrdinaryShares	35345	shares
CY2023	jfbr	Consideration Of Ordinary Shares considerationOfOrdinaryShares	13858	shares
CY2023	us-gaap	Stock Issued1 StockIssued1	288000	usd
CY2023	jfbr	Consideration Payable To Sellers Of Fort Products Ltd ConsiderationPayableToSellersOfFortProductsLtd	332000	usd
CY2023	jfbr	Consideration Payable To Seller Of Sci Sparc Nutraceuticals Inc ConsiderationPayableToSellerOfSciSparcNutraceuticalsInc	98000	usd
CY2022	jfbr	Substantial Modification Of Shareholders Loans Recorded In Equity SubstantialModificationOfShareholdersLoansRecordedInEquity	982000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	57000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	152000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 — GENERAL INFORMATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24pt"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Jeffs’ Brands Ltd (the “Company” or “Jeffs’ Brands”) was incorporated in Israel on March 7, 2021. As of the date of issuance of these financial statements the Company has five wholly owned subsidiaries — Smart Repair Pro (“Smart Pro”), Top Rank Ltd. (“Top Rank”), Jeffs’ Brands Holdings Inc. (“Jeffs’ Brands Holdings”), Fort Products Ltd. (“Fort”) and Fort Products LLC (“Fort US”) (the “Subsidiaries”). The Company and the Subsidiaries (“Group”) are engaged in the acquisition, improvement and operation of virtual stores (the “Brands”) mainly on the Amazon.com (“Amazon”) website.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">References to the Company hereinafter, unless the context otherwise provides, include Jeffs’ Brands and the Subsidiaries on a consolidated basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Smart Pro, a private corporation founded in the State of California, was established on December 20, 2017, and commenced its operations in June 2019. As of December 31, 2023, Smart Pro operated four brands on the Amazon website.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In April 2021, Top Rank, an Israeli company, was established as a wholly owned subsidiary of Jeffs’ Brands.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On February 23, 2023, Jeffs’ Brands Holdings Inc., was established and registered in Delaware as a wholly owned subsidiary of Jeffs’ Brands.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 9, 2023, the Company purchased all of the issued and outstanding share capital of Fort, a company incorporated under the laws of England and Wales. For additional information see note 5.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On April 23, 2023, Fort US, was incorporated and registered under the laws of the State of Delaware as a wholly owned subsidiary of Jeffs’ Brands Holdings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On February 23, 2023, the Company purchased approximately 49% of the issued and outstanding shares of common stock of SciSparc Nutraceuticals Inc. (“SciSparc U.S”). For additional information see note 7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Initial public offering</b></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 30, 2022, the Company completed its initial public offering (“IPO”), for additional information see note 13.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration risk</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Group’s activities are mainly conducted through Amazon’s commercial platform. Any material change, whether temporary or permanent, including changes in Amazon’s terms of use and/or its policies, may affect sales performance, and may have a material effect on the Group’s financial position and the results of its operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In addition, the Group is engaged with a small number of suppliers as part of the production process of its brands. Any material changes in the supply process, whether temporary or permanent, may affect sales performance, and may have a material effect on the Group’s financial position and the results of its operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the year ended December 31, 2023, the Group incurred a net loss of 4,598 thousand and cash flows used in operating activities were $ 2,668 thousand. As of December 31, 2023, the Group had an accumulated deficit of approximately $8,276 thousand.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Group has funded its operations to date through the sale of its products, through equity financings, loans from shareholders and other third parties, and sale of its Ordinary Shares and warrants. The Company intends to continue to finance its operating activities through the sale of products via its Brands and through raising additional capital, as needed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">On January 29, 2024, the Company entered into a private placement transaction (the “Private Placement”), pursuant to a Securities Purchase Agreement with certain institutional investors for aggregate gross proceeds of approximately $7.275 million, before deducting fees to the placement agent and other expenses payable by the Company in connection with the Private Placement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Management believes that expected cash flows are sufficient to support the Group’s current operations for more than 12 months from the issuance date of these consolidated financial statements.</p>
CY2023	jfbr	Bonus Shares And Reverse Share Split Description BonusSharesAndReverseShareSplitDescription	On February 23, 2023, the Company purchased approximately 49% of the issued and outstanding shares of common stock of SciSparc Nutraceuticals Inc. (“SciSparc U.S”).
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4598000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2668000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8276000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods and accompanying notes. The Group evaluates on an ongoing basis its assumptions including those related to sales allowances, fair value of intangible assets, useful lives of intangible assets, realizability of deferred tax assets, derivative liability and contingent liabilities, among others. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of the Group’s assets and liabilities.</p>
CY2023	us-gaap	Revenue Recognition Customer Acquisitions RevenueRecognitionCustomerAcquisitions	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>i.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset acquisition</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Group accounts for a transaction as an asset acquisition when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, or otherwise does not meet the definition of a business. Asset acquisition-related costs are capitalized as part of the asset or assets acquired.</p>
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	21000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	70000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	719000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	1163000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1211000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.0833	pure
CY2023	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	955	usd
CY2023Q4	us-gaap	Supplies Supplies	559000	usd
CY2022Q4	us-gaap	Supplies Supplies	641000	usd
CY2023Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	38000	usd
CY2022Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	130000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	8000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	597000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	779000	usd
CY2023Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	228000	usd
CY2023Q4	us-gaap	Other Inventory In Transit OtherInventoryInTransit	219000	usd
CY2022Q4	us-gaap	Other Inventory In Transit OtherInventoryInTransit	8000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2167000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1783000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2386000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1791000	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	730000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	570000	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	524000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	769000	usd
CY2023Q1	us-gaap	Capital Units CapitalUnits	2000000	eur
CY2023Q1	us-gaap	Capital Units CapitalUnits	2400000	usd
CY2023Q4	us-gaap	Obligation With Joint And Several Liability Arrangement Amount Outstanding ObligationWithJointAndSeveralLiabilityArrangementAmountOutstanding	332000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1991000	eur
CY2023Q1	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	2500	eur
CY2023Q1	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	3000	usd
CY2023Q3	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	3500	eur
CY2023Q3	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	4500	usd
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	138000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	127000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	95000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	43000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	138000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	127000	usd
CY2023	jfbr	Outstanding Due Amount OutstandingDueAmount	98000	usd
CY2023Q1	jfbr	Bonus Bonus	51000	usd
CY2023Q4	jfbr	Reduction Of Monthly Fee ReductionOfMonthlyFee	10000	usd
CY2023	us-gaap	Payments For Purchase Of Investment Operating Activity PaymentsForPurchaseOfInvestmentOperatingActivity	3189000	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	1249000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1940000	usd
CY2023Q1	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	288000	usd
	jfbr	Investment In Exchange Shareson InvestmentInExchangeShareson	288000	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	221000	usd
CY2023Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	67000	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	428000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	36000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	85000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	49000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	82000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	40000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	430000	usd
CY2023	jfbr	Revenue Sharing Payment Payable RevenueSharingPaymentPayable	140000	usd
CY2022	jfbr	Revenue Sharing Payment Payable RevenueSharingPaymentPayable	40000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	368000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	226000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1533000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	391000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	98000	usd
CY2022Q2	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	152000	usd
CY2022Q2	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.0999	pure
CY2021Q3	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.10	pure
CY2021Q3	jfbr	Short Term Debt Additional Interest ShortTermDebtAdditionalInterest	0.01	pure
CY2021Q3	jfbr	Aggregate Amount AggregateAmount	250000	usd
CY2021Q3	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	750000	usd
CY2021Q3	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	62000	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	137000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	14000	usd
CY2022Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	1000000	usd
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	400000	usd
CY2022Q2	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	200000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	8200000	usd
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	403504	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.14
CY2022Q4	jfbr	Percentage Of Gross Revenues PercentageOfGrossRevenues	0.023	pure
CY2023	jfbr	Revenue Sharing Payment RevenueSharingPayment	269000	usd
CY2022	jfbr	Revenue Sharing Payment RevenueSharingPayment	40000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	137000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	8220000	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	2822000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	-3319000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2216000	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	841000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1375000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	94000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-53000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-18000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-115000	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-53000	usd
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	209088	shares
CY2022Q3	us-gaap	Dividends And Interest Paid DividendsAndInterestPaid	393000	usd
CY2023	jfbr	Effective Income Tax Rate Blended Corporate Rate EffectiveIncomeTaxRateBlendedCorporateRate	0.28	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2866000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2081000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1096000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1700000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-126000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-465000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4566000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2207000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1561000	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	7000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	78000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	12000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	94000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	85000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	12000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-18000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-115000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4566000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2207000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1561000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1050000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-508000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-359000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-46000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-110000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-78000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1128000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	612000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	416000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	388000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	110000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	28000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	32000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1476000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	890000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1892000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1032000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1696000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	890000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	196000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	142000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	28000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	32000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	28000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	32000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	168000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	110000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	6418000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3870000	usd
CY2022Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	664.0547
CY2022Q1	jfbr	Aggregate Issuance Share AggregateIssuanceShare	6630547	usd
CY2022Q1	jfbr	Authorized Share Capital AuthorizedShareCapital	100000000	usd
CY2022Q1	jfbr	Reverse Shares ReverseShares	43567567	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On May 3, 2022, the Company’s Board of Directors approved a 0.806-for-1 reverse split of its issued and outstanding Ordinary Shares, effective as of May 3, 2022, pursuant to which holders of the Company’s Ordinary Shares received 0.806 of an Ordinary Share for every one Ordinary share.
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On June 16, 2022, the Company’s Board of Directors approved a 1-for-1.85 reverse split of our issued and outstanding Ordinary Shares, effective as of June 16, 2022, pursuant to which holders of our Ordinary Shares received one Ordinary Share for every 1.85 Ordinary Shares held as of such date.
CY2022Q3	jfbr	Initial Exercise Price Expire InitialExercisePriceExpire	P5Y
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.14
CY2022Q3	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	14.14
CY2022Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	14.14
CY2022Q4	jfbr	Revenues Percentage RevenuesPercentage	0.023	pure
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	42.42
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4000	usd
CY2022Q1	jfbr	Issuance Of Bonus Shares IssuanceOfBonusShares	1	pure
CY2022Q1	jfbr	Aggregate Issuance Shares AggregateIssuanceShares	7	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	186718	shares
CY2023	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	841000	usd
CY2022	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	2822000	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	4000	usd
CY2021	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	14000	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	845000	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2822000	usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	14000	usd
CY2022	us-gaap	Financing Interest Expense FinancingInterestExpense	83000	usd
CY2021	us-gaap	Financing Interest Expense FinancingInterestExpense	77000	usd
CY2021	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	75000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	37000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	85000	usd
CY2023	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	91000	usd
CY2022	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	156000	usd
CY2021	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	10000	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	203000	usd
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	381000	usd
CY2023	us-gaap	Other Noninterest Expense OtherNoninterestExpense	10000	usd
CY2022	us-gaap	Other Noninterest Expense OtherNoninterestExpense	38000	usd
CY2021	us-gaap	Other Noninterest Expense OtherNoninterestExpense	15000	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-221000	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	322000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	517000	usd
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	643000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	523000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2305000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-629000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4598000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2201000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1540000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1184484	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	663411	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	413192	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.88
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.73
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7232444	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7232444	shares
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	249000	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	358000	usd
CY2023	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	282000	usd
CY2022	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	172000	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	180000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	218000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	545000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	395000	usd
CY2023	jfbr	Revenuesharingpaymentincludedingeneralandadministrative Revenuesharingpaymentincludedingeneralandadministrative	40000	usd
CY2022	jfbr	Revenuesharingpaymentincludedingeneralandadministrative Revenuesharingpaymentincludedingeneralandadministrative	6000	usd
CY2023	us-gaap	Other Income OtherIncome	-255000	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	203000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1041000	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1352000	usd
CY2022Q3	jfbr	Bonus Bonus	480000	ils
CY2022Q3	jfbr	Bonus Bonus	140000	usd
CY2022Q4	jfbr	Consultancy Services Fees ConsultancyServicesFees	57500	ils
CY2022Q4	jfbr	Consultancy Services Fees ConsultancyServicesFees	16500	usd
CY2022Q4	jfbr	Bonus Bonus	425000	ils
CY2022Q4	jfbr	Bonus Bonus	121000	usd
CY2022Q4	jfbr	Percentage Of Gross Proceed PercentageOfGrossProceed	0.07	pure
CY2022Q4	jfbr	Percentage Of Total Consideration Paid PercentageOfTotalConsiderationPaid	0.08	pure
CY2022Q4	jfbr	Undefined Period Of Time UndefinedPeriodOfTime	P3Y
CY2023Q1	jfbr	Consultancy Services Fees ConsultancyServicesFees	352000	usd
CY2022Q2	jfbr	Percentage Lease And Maintenance Expenses Related PercentageLeaseAndMaintenanceExpensesRelated	0.50	pure
CY2022	us-gaap	Other Labor Related Expenses OtherLaborRelatedExpenses	86000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.50	pure
CY2023	jfbr	Employee Provided Services EmployeeProvidedServices	10000	ils
CY2023	jfbr	Employee Provided Services EmployeeProvidedServices	3000	usd
CY2023Q1	jfbr	Bonus Bonus	51000	usd
CY2023Q4	jfbr	Reduction Of Monthly Fee ReductionOfMonthlyFee	10000	usd
CY2023	jfbr	Outstanding Payable OutstandingPayable	12000	usd
CY2023	jfbr	Outstanding Due Amount OutstandingDueAmount	98000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10008000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5859000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6509000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2900036	shares
CY2023	jfbr	Percentage Of Gross Cash Proceeds PercentageOfGrossCashProceeds	0.085	pure
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent		usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2022Q4	us-gaap	Other Investments OtherInvestments		usd
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal		usd
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal		usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2022	jfbr	Other Operating Incomeloss OtherOperatingIncomeloss		usd
CY2021	jfbr	Other Operating Incomeloss OtherOperatingIncomeloss		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.32
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.73
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.88
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	413192	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	663411	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2023	jfbr	Issuance Costs On Derivative Liabilities IssuanceCostsOnDerivativeLiabilities		usd
CY2021	jfbr	Issuance Costs On Derivative Liabilities IssuanceCostsOnDerivativeLiabilities		usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
CY2023	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent		usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2022	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments		usd
CY2021	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments		usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2023	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2023	jfbr	Deferred Offering Costs Included In Other Payables DeferredOfferingCostsIncludedInOtherPayables		usd
CY2022	jfbr	Deferred Offering Costs Included In Other Payables DeferredOfferingCostsIncludedInOtherPayables		usd
CY2023	jfbr	Sharebased Compensation Included In Deferred Offering Costs SharebasedCompensationIncludedInDeferredOfferingCosts		usd
CY2022	jfbr	Sharebased Compensation Included In Deferred Offering Costs SharebasedCompensationIncludedInDeferredOfferingCosts		usd
CY2023	jfbr	Issuance Of Ordinary Shares Upon Conversion Of Shareholders Loans IssuanceOfOrdinarySharesUponConversionOfShareholdersLoans		usd
CY2021	jfbr	Issuance Of Ordinary Shares Upon Conversion Of Shareholders Loans IssuanceOfOrdinarySharesUponConversionOfShareholdersLoans		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	jfbr	Consideration Payable To Sellers Of Fort Products Ltd ConsiderationPayableToSellersOfFortProductsLtd		usd
CY2021	jfbr	Consideration Payable To Sellers Of Fort Products Ltd ConsiderationPayableToSellersOfFortProductsLtd		usd
CY2022	jfbr	Consideration Payable To Seller Of Sci Sparc Nutraceuticals Inc ConsiderationPayableToSellerOfSciSparcNutraceuticalsInc		usd
CY2021	jfbr	Consideration Payable To Seller Of Sci Sparc Nutraceuticals Inc ConsiderationPayableToSellerOfSciSparcNutraceuticalsInc		usd
CY2023	jfbr	Substantial Modification Of Shareholders Loans Recorded In Equity SubstantialModificationOfShareholdersLoansRecordedInEquity		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent		usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount		usd
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative		usd
CY2022	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
CY2023	us-gaap	Financing Interest Expense FinancingInterestExpense		usd
CY2023	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative		usd
CY2022	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense		usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss		usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss		usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1184484	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	413192	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	663411	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.32
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.73
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.88
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2022	us-gaap	Other Income OtherIncome		usd
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001885408

Files In Submission

Name	View Source	Status
0001213900-24-028253-index-headers.html	Edgar Link	pending
0001213900-24-028253-index.html	Edgar Link	pending
0001213900-24-028253.txt	Edgar Link	pending
0001213900-24-028253-xbrl.zip	Edgar Link	pending
ea0202280-20f_jeffs.htm	Edgar Link	pending
ea020228001ex12-1_jeffs.htm	Edgar Link	pending
ea020228001ex12-2_jeffs.htm	Edgar Link	pending
ea020228001ex13-1_jeffs.htm	Edgar Link	pending
ea020228001ex13-2_jeffs.htm	Edgar Link	pending
ea020228001ex15-1_jeffs.htm	Edgar Link	pending
ea020228001ex2-8_jeffs.htm	Edgar Link	pending
ea020228001ex4-20_jeffs.htm	Edgar Link	pending
ea020228001ex4-26_jeffs.htm	Edgar Link	pending
ea020228001ex8-1_jeffs.htm	Edgar Link	pending
ea020228001ex97_jeffs.htm	Edgar Link	pending
ex4-26_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
jfbr-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
jfbr-20231231_cal.xml	Edgar Link	unprocessable
jfbr-20231231_def.xml	Edgar Link	unprocessable
jfbr-20231231_lab.xml	Edgar Link	unprocessable
jfbr-20231231_pre.xml	Edgar Link	unprocessable
ea0202280-20f_jeffs_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JFBR
Jeffs' Brands Ltd Stock $jfbr

2023 Q4 Form 20-F Financial Statement

#000121390024028253 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JFBR Jeffs' Brands Ltd Stock $jfbr

2023 Q4 Form 20-F Financial Statement

#000121390024028253 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JFBR
Jeffs' Brands Ltd Stock $jfbr